Fascination About Tyrosinase-IN-12
MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre study To judge a number of intravenous doses of sifalimumab, in Grownup sufferers with dermatomyositis or polymyositis (NCT00533091). Primary trial goals were being to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyosi